iA Global Asset Management Inc. Decreases Holdings in Abbott Laboratories $ABT

iA Global Asset Management Inc. reduced its position in Abbott Laboratories (NYSE:ABT) by 98.1% in the 1st quarter, HoldingsChannel.com reports. The firm owned 2,292 shares of the healthcare product maker’s stock after selling 116,374 shares during the period. iA Global Asset Management Inc.’s holdings in Abbott Laboratories were worth $235,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Freemont Management S.A. increased its position in Abbott Laboratories by 197.2% during the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after buying an additional 7,100 shares in the last quarter. PFA Pension Forsikringsaktieselskab purchased a new stake in shares of Abbott Laboratories in the fourth quarter valued at $116,580,000. Danica Pension Livsforsikringsaktieselskab purchased a new stake in shares of Abbott Laboratories in the third quarter valued at $185,640,000. Thrivent Financial for Lutherans boosted its stake in shares of Abbott Laboratories by 24.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock valued at $30,931,000 after acquiring an additional 48,286 shares during the last quarter. Finally, Mn Services Vermogensbeheer B.V. increased its position in Abbott Laboratories by 2.1% during the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 671,743 shares of the healthcare product maker’s stock worth $84,163,000 after purchasing an additional 13,543 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was acquired at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Philip P. Boudreau bought 2,200 shares of the company’s stock in a transaction that occurred on Thursday, April 23rd. The shares were acquired at an average cost of $91.50 per share, with a total value of $201,300.00. Following the transaction, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Citigroup reduced their target price on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Argus cut their price objective on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, April 21st. Wells Fargo & Company reduced their price objective on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Royal Bank Of Canada lowered their target price on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Finally, Robert W. Baird began coverage on Abbott Laboratories in a report on Wednesday. They issued an “outperform” rating and a $121.00 price target for the company. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $118.42.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $95.25 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The firm has a market capitalization of $165.91 billion, a price-to-earnings ratio of 26.68, a price-to-earnings-growth ratio of 1.64 and a beta of 0.61. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company has a 50 day moving average price of $88.95 and a 200 day moving average price of $104.35.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Sell-side analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 70.59%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.